Form 4: Cerus CEO Greenman Granted 1.2M RSUs

Cerus Corporation's President and CEO, William M. Greenman, was granted 1.2 million restricted stock units, aligning executive incentives with long-term company performance.

Summary

• William M. Greenman, President and CEO, and a Director of Cerus Corporation (CERS), was granted 1,200,000 Restricted Stock Units (RSUs).
• The RSUs represent a contingent right to receive one share of common stock per RSU.
• The vesting schedule for the RSUs is in two annual installments: 34% on March 12, 2027, and 66% on March 12, 2028, contingent on continuous service.
• Following this transaction, Greenman beneficially owns 5,331,167 shares of common stock.
• This total includes 5,318 shares purchased under the Employee Stock Purchase Plan (ESPP) on August 29, 2025, and 10,004 shares purchased under the ESPP on February 27, 2026.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's interests with long-term company performance and shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 1,200,000 Restricted Stock Units (RSUs) to the President and CEO, William M. Greenman, strengthens executive alignment with long-term shareholder interests.
• The vesting schedule, extending through March 2028, incentivizes continuous service and sustained performance.
• The inclusion of shares purchased under the Employee Stock Purchase Plan (ESPP) indicates ongoing personal investment by the CEO in the company's equity.

Negatives

• The RSU grant, while common for executive compensation, represents potential future dilution for existing shareholders upon vesting.

Future Outlook

The RSU grant's vesting schedule indicates a forward-looking incentive structure, with significant portions of the grant vesting in March 2027 and March 2028, contingent on the CEO's continuous service. This suggests a commitment to long-term executive retention and performance.

Industry Context

StockSavvy.ai notes that executive equity grants, particularly Restricted Stock Units (RSUs), are a standard component of compensation packages in the biotechnology and medical device sectors, aiming to align leadership incentives with long-term shareholder value creation. This grant to Cerus's CEO is consistent with practices observed across the industry for retaining key talent and motivating performance over multi-year horizons.

Comparison to Industry Standards

• The grant of 1.2 million RSUs to a CEO of a company like Cerus (a biotechnology company focused on blood safety) is a substantial equity award, comparable in scale to grants seen at similar-sized or growth-stage biotech firms. For instance, CEOs at companies like Inovio Pharmaceuticals or Dynavax Technologies often receive multi-million dollar equity packages, including RSUs, tied to performance and tenure.
• The vesting schedule (34% in 2027, 66% in 2028) is a common multi-year vesting structure, designed to ensure long-term commitment, similar to those observed at companies such as Exact Sciences or Guardant Health for their executive teams.
• The inclusion of ESPP purchases by the CEO further demonstrates personal investment, a positive sign often seen in well-regarded management teams across the industry.

Related Party Transactions

• The grant of 1,200,000 Restricted Stock Units (RSUs) to William M. Greenman, the President and CEO, constitutes a related party transaction as it involves compensation to a key executive.
• The purchases of 5,318 and 10,004 shares under the Employee Stock Purchase Plan (ESPP) by the CEO are also related party transactions, representing equity acquisitions by an insider.

Stakeholder Impact

• Shareholders: Potential future dilution upon RSU vesting, but also increased alignment of CEO's interests with long-term share price appreciation.
• Employees: The CEO's participation in the ESPP and receipt of RSUs may signal confidence in the company's future, potentially boosting employee morale.
• Management: The RSU grant provides a significant long-term incentive for the CEO, encouraging continued leadership and strategic execution.

Next Steps

• 34% of the 1,200,000 RSUs are scheduled to vest on March 12, 2027.
• 66% of the 1,200,000 RSUs are scheduled to vest on March 12, 2028.

Key Dates

Recommendation

The filing details a routine executive compensation event (RSU grant) and minor ESPP purchases, which are generally expected and do not fundamentally alter the company's financial outlook or operational trajectory. While the grant aligns executive incentives, it does not present new information warranting a change in investment stance based solely on this Form 4. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Cerus Corporation, CERS, William Greenman, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Employee Stock Purchase Plan, ESPP, Corporate Governance